Conference Coverage
about 2 months ago
Neoadjuvant SAbR shows promising outcomes in RCC with tumor thrombusabout 2 months ago
Mark Tyson, MD shares promising BOND-003 results in papillary NMIBCabout 2 months ago
Cretostimogene demonstrates safety, efficacy in papillary NMIBC cohortabout 2 months ago
SYNC-T demonstrates high bone metastasis resolution in phase 1 cohortabout 2 months ago
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBCabout 2 months ago
NDV-01 produces robust 9-month results in high-risk NMIBCLatest News
Jan 23, 2026 | Feature
Practical guide to female pelvic organ–sparing radical cystectomy
ProFam-Risk registry aims to establish model for personalized prostate cancer prevention
Jan 22, 2026
Pearls & Perspectives: Navigating Evidence Gaps and Innovation in OAB Care, With Ariana Smith, MD
Jan 22, 2026
CaverSTIM device shows initial promise for post-prostatectomy erectile dysfunction
Jan 21, 2026
FDA grants 510(k) clearance to Break Wave lithotripsy device for kidney stones
Jan 21, 2026
Advertisement
Shorts
0:48
Daniel Antonio González Padilla, MD, on the end points of the CREST and POTOMAC trials
16 hours ago
by
Daniel Antonio González Padilla, MD
1:14
Ridwan I. Alam, MD, MPH, on his approach to prostate cancer screening
2 days ago
by
Ridwan I. Alam, MD, MPH
1:04
Kalyani Narra, MD, outlines gaps in referrals for genetic counseling in prostate cancer
3 days ago
by
Kalyani Narra, MD
1:09
Aleece Fosnight, MSPAS, PA-C, on hydration and pelvic floor physical therapy for bladder symptoms
4 days ago
by
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES
1:15
Archan Khandekar, MD, discusses the use of augmented reality with prostate biopsy
5 days ago
by
Archan Khandekar, MD
0:53
Aleece Fosnight, MSPAS, PA-C, on evaluating cyclical bladder symptoms in women
8 days ago
by
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES
0:35
Sevann Helo, MD, shares her advice for urology residency applicants
9 days ago
by
Sevann Helo, MD
1:08
Pearls & Perspectives: Amy Pearlman, MD, and Nicoletta Heidegger, MA, MEd, LMFT, on sexual medicine myths
10 days ago
by
Amy M. Pearlman, MD
1:24
Jennifer Miles-Thomas, MD, URPS, MBA, on academic care centers expanding into communities
10 days ago
by
Jennifer Miles-Thomas, MD, URPS, MBA
1:19
Ridwan I. Alam, MD, MPH, on the PHI test in men with PSA between 10 and 20 ng/mL
12 days ago
by
Ridwan I. Alam, MD, MPH
From GSM guidance to HRT reform: A landmark year for women’s health
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
Inguinal lymph node dissection in penile cancer
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
Inside HoLEP: Irina Jaeger, MD, discusses patient selection and technique
Jaeger emphasizes that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication.
Podcasts
Videos
Urology Times Digital Edition
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.
"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.
The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.
The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
Continuing Medical Education
Advertisement
All News
Advertisement
The ARID platform is evaluating the safety and efficacy of the Voro Urologic Scaffold in minimizing stress urinary incontinence following robot-assisted radical prostatectomy.
The phase 3 BiPASS trial is assessing earlier use of 68Ga-PSMA-PET imaging in the pre-biopsy setting.
Enrollment in the ongoing pivotal QUILT-2.005 trial has now reached 85%.
In this episode of The UroOnc Minute, host Adam B. Weiner, MD, speaks with Stephen J. Freedland, MD, about the role of diet and nutrition in prostate cancer risk and outcomes.
The Safety Review Committee has recommended that the trial proceed with the cohort expansion phase with no modifications to the protocol.
The next step is to prospectively validate the model in real-world clinical settings or within ongoing clinical trials.
Image-guided radiotherapy with reduced target margins may improve some dosimetric parameters and patient-reported urinary symptoms.
The ARTISAN trial includes both 177Lu-PSMA naïve and 177Lu-PSMA experienced cohorts.
The phase 2 study is looking to evaluate nadofaragene firadenovec in combination with the investigational light-activated small molecule TLD-1433 (Ruvidar).
Advertisement
Treatment failure occurred in 46% of patients in the high-risk group vs 21% of patients in the low-risk group.
The study is intended to support potential label expansion of testosterone undecanoate in men aged 65 to 80 years with hypogonadism.
Enolen is currently under investigation in a phase 1 trial to assess its safety and efficacy in delivering enzalutamide locally into the prostate.
The phase 2 PROHEAR trial is assessing the safety and efficacy of ACOU085 in preventing ototoxic hearing loss induced by cisplatin-based chemotherapy.
The results from this study are expected to support an application to the FDA for premarket approval of the Butterfly device.
Advertisement
Advertisement
Trending on Urology Times
1
Ridwan I. Alam, MD, MPH, discusses combining PHI and MRI to predict prostate cancer risk
2
FDA grants 510(k) clearance to Break Wave lithotripsy device for kidney stones
3
Targeting BCG resistance in high-risk NMIBC
4
CaverSTIM device shows initial promise for post-prostatectomy erectile dysfunction
5